EPSILON-BIOTECH

Active

Private limited companyfounded 1994active for 31 yearsBeverzakbroekweg 91, 3520 Zonhoven, BelgiumKBO/BCE: BE 0453.963.661

Summary

EPSILON-BIOTECH has been active since 1994 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €220,466 and a net result of €17,279. Equity is growing by about 23% per year across the filed financial years. Its solvency ranks better than 84% of 613 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).

Risk analysisFollow Report Compare

EPSILON-BIOTECHActiveChecked score 96/100

Risk analysis Report Compare

Activity

Other research and development on natural sciences

NACE 72109

4th oldest company in Limburg, Research and development sector1 site

Size

€244,785total assets 2025

Equity: €220,466
Profit: €17,279

Turnover not published (abbreviated or micro format)

Financial health

96 Excellent Checked score 2025

Bankruptcy probabilitywithin 12 months: < 0.1%

Structure

2025 accounts 31 days early2 deeds in the Belgian Official Gazette

Why 96raises riskProfit of €17,279 (financial year 2025)lowers riskLiquidity: current ratio 8.53, cash €91,519Equity €220,466 (90.1% of total assets)Founded in 1994Show the evidence

Checked score

Score 2025

96 / 100

Excellent

Probability in this band: under 0.55%

Financially better than 71% of its sector peers (NACE 72, micro)

Every signal that counts is listed under Signals.

Financial strength · tick = 2024

Strong

Solvency 100=

equity 90.1% of total assets

Liquidity 97+18

short-term debt 9.9% · cash 37.4%

Profitability 78-16

return on assets 7.1%

Bankruptcy probability, 12 months

< 0.1% Very low

0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.1% (935 companies, NACE 72, micro)

Last 24 months 11-2024: < 0.1% 12-2024: < 0.1%● unchanged vs 11-2024 01-2025: < 0.1%● unchanged vs 12-2024 02-2025: < 0.1%● unchanged vs 01-2025 03-2025: < 0.1%● unchanged vs 02-2025 04-2025: < 0.1%● unchanged vs 03-2025 05-2025: < 0.1%● unchanged vs 04-2025 06-2025: < 0.1%● unchanged vs 05-2025 07-2025: < 0.1%● unchanged vs 06-2025lowest value 08-2025: < 0.1%● unchanged vs 07-2025lowest value 09-2025: < 0.1%● unchanged vs 08-2025lowest value 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025highest value 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026 08-2026: < 0.1%● unchanged vs 07-2026 09-2026: < 0.1%● unchanged vs 08-2026 10-2026: < 0.1%● unchanged vs 09-2026

Credit of up to €21,000 on 30-day terms is acceptable

Liquidity ample (current ratio 8.53, compared with 7.05 in 2024, above the usual 1.5; short-term debt: 9.9% and cash: 37.4% of total assets), and 9.9% of the assets are financed with debt and provisions.

How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, micro): better than 83% on solvency, 87% on liquidity, 52% on profitability and 60% on growth.

The bankruptcy probability was computed on 26-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.

lowers riskraises riskneutral

Liquidity: current ratio 8.53, cash €91,519

NBB · annual accounts

Equity €220,466 (90.1% of total assets)

NBB · annual accounts

Founded in 1994

Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.

KBO

Profit of €17,279 (financial year 2025)

NBB · annual accounts

Latest accounts filed on time

The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 31-12-2025, 31 days ahead of the deadline.

NBB · 10 filings

Deviation from the deadline

2025

31 days early

2024

29 days early

2023

8 days early

2022

8 days early

2021

47 days early

2019

73 days early

2018

64 days early

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 37 days before the deadline; the sector median (NACE 72) for financial year 2024 is 13 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)

Next filing not due yet

The financial year that closed on 30-06-2026 is due by 31-01-2027. Nothing is late today. The company usually files around 2 January (5 of the last 5 filed years within 30 days of that day).

Companies Code · seven months

Where today falls in the filing period

30-06-2026 year end27-10-2026 today31-01-2027 deadline

No strike-offs in the KBO publications

Searched since 2021.

KBO publications · our coverage

31-12-2025 Annual accounts filedfinancial year 2025 · micro…
02-01-2025 Annual accounts filedfinancial year 2024 · micro…
30-06-2024 Equity above €200,000equity €203,187 ▲29.7%

Key points

Positive: 4th oldest company in Limburg, Research and development sectorin the Checked rankings No. 4 View
Positive: Filed on time since financial year 2017accounts within the deadline every year 8 years View
Positive: 7 profitable years in a rowprofit 2025: €17,279 7 years View

By topic

Financials

Financial year: 2025
Total assets: €244,785
Profit: €17,279
Solvency: 90.1%

Total assets▲ 6.4%

Net result

20182025

Go to Financials

Timeline

Events: 35
Since: 1996
Next accounts: by 31-01-2027

23-01-2024Annual accounts filed
30-06-2023Highest result from 2018 to 2025
30-06-2023Equity above €150,000

Go to Timeline

Company details

Sites: 1

Legal form: Private limited company
Activity: Other research and development on natural sciencesNACE 72109
Founded: 06-12-1994
Year ends: 30-06
Peppol: Reachable for e-invoices

Go to Company details

Key facts about EPSILON-BIOTECH

What is the company number of EPSILON-BIOTECH?: 0453.963.661. In Belgium the VAT number is the company number with BE in front: BE 0453.963.661.
Where is EPSILON-BIOTECH based?: The registered office is at Beverzakbroekweg 91, 3520 Zonhoven.Company details
What does EPSILON-BIOTECH do?: According to the KBO register, the main activity is other research and development on natural sciences (NACE 72109).
What is the legal form of EPSILON-BIOTECH?: Private limited company (BV).
When was EPSILON-BIOTECH founded?: On 06-12-1994.
Is EPSILON-BIOTECH still active?: Yes, EPSILON-BIOTECH is an active enterprise in the KBO register.
How many employees does EPSILON-BIOTECH have?: On average 0.5 full-time equivalents in financial year 2021, according to the filed annual accounts.Financials
What is the turnover of EPSILON-BIOTECH?: Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.
Is EPSILON-BIOTECH profitable?: In financial year 2025, EPSILON-BIOTECH made a profit of €17,279.
Where can I find the annual accounts of EPSILON-BIOTECH?: EPSILON-BIOTECH filed 30 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of EPSILON-BIOTECH due?: By 31-01-2027, for financial year 2026.Timeline